Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.

Mol Cancer Ther · 2022 · PMC9377761 · PMID 35500018

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In terms of overall tumor growth and tumor cell proliferation, the combination of antiangiogenic agents with nal-IRI or IRI showed a trend to additive inhibitory response, but differences were not statistically significant compared with single-agent therapies.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.